Gilead Sciences, Inc. (GILD)

Environment story

Gilead's 10-K discloses no quantified Scope 1/2/3 emissions data, no numeric renewable-electricity percentage, and no dated net-zero target, resulting in maximum deductions under the disclosure-based scoring rubric. The filing acknowledges climate-transition risk (decarbonization of healthcare systems, EU 2050 targets) as a cost factor rather than a company-specific commitment. No verified physical decarbonization capex was identified in the provided text, though the company references facility investments (e.g., La Verne, Cork) tied to manufacturing capacity rather than confirmed emissions reduction.

Social story

Gilead discloses an inclusion council, employee resource groups, an annual pay-equity review, and a Total Rewards benefits package, but does not disclose a CEO-to-median-worker pay ratio, workforce diversity percentages, or turnover metrics in the provided filings. No union-suppression activity, strikes, or NLRB complaints are referenced in the source documents. Board-level diversity (3 of 9 directors are women; 4 of 9 self-identify as ethnically diverse) exceeds the 30% threshold used in this rubric, so no leadership-diversity deduction applies. Supply-chain human-rights risk categories such as cobalt/lithium mining are not applicable to Gilead's biopharmaceutical business model.

Governance story

Gilead maintains a single-class common share structure and a board that is 8 of 9 (89%) independent, exceeding the 75% independence threshold, so no deduction applies on either count. The company has engaged directly with the U.S. administration on drug-pricing policy, including a December 2025 agreement pausing Section 232 tariffs and implementing most-favored-nation pricing for select products — a notable regulatory-engagement item though not clearly classifiable as anti-consumer-protection lobbying. Ongoing 340B contract-pharmacy program disputes and related HHS enforcement posture represent an active regulatory/legal exposure area, resulting in a modest deduction.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Gilead Sciences, Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Gilead Sciences, Inc. in the app for interactive charts and portfolio building.

More in Healthcare